Drug Profile
Research programme: erythropoietin long-acting - Genova
Alternative Names: Nova-EPOLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genova Biotech Company
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in China (Parenteral)
- 12 Jul 2011 Preclinical trials in Anaemia in China (Parenteral)